Janeen Doyle
Vermögen: 1 Mio $ am 31.07.2026
Vermögen: 1 Mio $ am 31.07.2026
Ms. Janeen Doyle is a Chief Corporate & Business Development Officer at Janux Therapeutics, Inc. Ms. Doyle was previously employed as a Senior VP-Strategy & Business Development by Bristol Myers Squibb Co. and a Senior VP-Strategy & Business Development by Celgene Corp.
She received her undergraduate degree from Moravian College and an MBA from the University of Scranton.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
JANUX THERAPEUTICS, INC. 0,13 % | 02.06.2026 | 75.941 ( 0,13 % ) | 1 Mio $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Corporate Officer/Principal | 15.05.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Moravian College
Moravian College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Scranton
University of Scranton Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company that develops precision engineered immunotherapies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen